Home / Health / Consistent Lupus Meds Cut Heart Risk
Consistent Lupus Meds Cut Heart Risk
21 Sep
Summary
- Lupus patients face higher heart disease risk if they skip medication.
- Consistent hydroxychloroquine use significantly lowers heart disease risk.
- Monitoring HCQ blood levels can optimize treatment and prevent heart events.
Lupus patients face an elevated risk of heart disease, but consistent medication adherence can substantially mitigate this threat. A recent study highlights that individuals who do not regularly take hydroxychloroquine (HCQ), the primary treatment for lupus, exhibit a greater risk of developing heart conditions.
This research underscores the importance of targeted interventions to improve long-term adherence to HCQ. Lead researcher Dr. Shivani Garg noted that patients often struggle with lifelong daily medication. Providing clear data on HCQ levels and their impact on heart health can empower patients to make informed decisions.
The study examined 248 lupus patients, assessing their heart disease risk against their HCQ adherence. Findings indicated that patients with very low HCQ blood levels and fewer prescription refills experienced a higher risk of heart disease within one to two years.
While the increased risk was modest, it is significant given the patients' relatively young average age of 47. This finding offers a clear rationale for optimizing HCQ use and dosing to prevent cardiovascular events, suggesting a move beyond one-size-fits-all treatment.
